<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tenofovir alafenamide and emtricitabine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tenofovir alafenamide and emtricitabine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tenofovir alafenamide and emtricitabine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="107877" href="/d/html/107877.html" rel="external">see "Tenofovir alafenamide and emtricitabine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="108768" href="/d/html/108768.html" rel="external">see "Tenofovir alafenamide and emtricitabine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F46363032"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">HIV-1 and hepatitis B coinfection:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe acute exacerbations of hepatitis B (HBV) have been reported in HBV-infected individuals who have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate, and may occur with discontinuation of emtricitabine/tenofovir alafenamide. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in individuals who are infected with HBV and discontinue emtricitabine/tenofovir alafenamide. If appropriate, anti-HBV therapy may be warranted.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risk of drug resistance with use for preexposure prophylaxis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Emtricitabine/tenofovir alafenamide used for HIV-1 preexposure prophylaxis (PrEP) must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use. Drug-resistant HIV-1 variants have been identified with the use of emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP following undetected acute HIV-1 infection. Do not initiate emtricitabine/tenofovir alafenamide for HIV-1 PrEP if signs or symptoms of acute HIV-1 infection are present unless negative infection status is confirmed.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F46443599"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Descovy</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872168"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Descovy</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F46363035"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV);</li>
<li>
                        Antiretroviral, Reverse Transcriptase Inhibitor, Nucleotide (Anti-HIV)</li></ul></div>
<div class="block doa drugH1Div" id="F46507955"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="61f04a2f-8f09-49e6-9832-b8cb7bf4617e">HIV-1/hepatitis B co-infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1/hepatitis B co-infection, treatment (off-label use): Oral:</b> One tablet (emtricitabine 200 mg/tenofovir alafenamide 25 mg) once daily in combination with other antiretroviral agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment:</b>
<b>Oral:</b> One tablet (emtricitabine 200 mg/tenofovir alafenamide 25 mg) once daily, in combination with other antiretroviral agents.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee761c85-c3db-4749-b56b-b4bc649f5d01">HIV-1 infection, preexposure prophylaxis in men and transgender women</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, preexposure prophylaxis in men and transgender women:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Some experts reserve use for those with or at risk of renal dysfunction (CrCl 30 to &lt;60 mL/minute), osteopenia, or osteoporosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33052386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33052386'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> One tablet (emtricitabine 200 mg/tenofovir alafenamide 25 mg) once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-32711800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-32711800'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991379"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dose adjustments for altered kidney function</i></b>
<b>
<i> prior to treatment initiation</i></b>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Kidney function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes. Although the manufacturer’s labeling of individual agent emtricitabine suggests adjustments to the dosing interval when CrCl &lt;50 mL/minute, clinical and pharmacokinetic studies suggest that it can be used at usual recommended doses/intervals when CrCl ≥30 mL/minute and in patients receiving hemodialysis; monitor for GI (eg, nausea) and CNS-related adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30555051','lexi-content-ref-27673443','lexi-content-ref-26627107','lexi-content-ref-28867499','lexi-content-ref-24492366','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30555051','lexi-content-ref-27673443','lexi-content-ref-26627107','lexi-content-ref-28867499','lexi-content-ref-24492366','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function: Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥30 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27673443','lexi-content-ref-26627107','lexi-content-ref-28867499','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27673443','lexi-content-ref-26627107','lexi-content-ref-28867499','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: Use is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>): </b>Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Emtricitabine (~30% removed over 3 hours); tenofovir alafenamide (no data on % removed):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>No dosage adjustment necessary. When a scheduled dose falls on a hemodialysis day, administer after hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis: Oral:</b> Use not recommended (has not been studied) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> There are no data available in patients on CRRT (has not been studied). Although some removal of emtricitabine and tenofovir are expected based on physicochemical characteristics, no dosage adjustment is likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> There are no data available in patients on PIRRT (has not been studied). Although some removal of emtricitabine and tenofovir are expected based on physicochemical characteristics, no dosage adjustment is likely to be necessary. When a scheduled dose falls on a PIRRT day, administer after PIRRT session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Nephrotoxicity during treatment:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">Tenofovir alafenamide has been associated with acute kidney injury, proximal tubular nephropathy, and Fanconi syndrome. Although kidney injury is less common with tenofovir alafenamide than tenofovir disoproxil fumarate, discontinue use in patients who develop clinically significant decreases in kidney function or evidence of Fanconi syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28885375','lexi-content-ref-34419091','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28885375','lexi-content-ref-34419091','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988542"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild-to-moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary. </p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F46507958"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F46507956"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="108768" href="/d/html/108768.html" rel="external">see "Tenofovir alafenamide and emtricitabine: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Multiple tablet strengths are available and contain different amounts of each component; use caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment:</b>
<b>Note:</b> In patients weighing &lt;35 kg, efficacy has not been established for coadministration with an HIV protease inhibitor administered with either ritonavir or cobicistat. Gene mutation and antiretroviral resistance patterns should be evaluated (refer to https://www.iasusa.org for more information) when necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Children weighing 14 to &lt;25 kg: Oral: Emtricitabine 120 mg and tenofovir alafenamide 15 mg per tablet: One tablet once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents weighing ≥25 kg: Oral: Emtricitabine 200 mg and tenofovir alafenamide 25 mg per tablet: One tablet once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e248a7aa-c106-402d-a21a-b53738bf5486">HIV-1 infection, preexposure prophylaxis in uninfected high-risk individuals</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV</b>
<b>-1 infection, preexposure prophylaxis (PrEP) in uninfected high-risk individuals:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Patients should be confirmed HIV-negative immediately prior to initiation of therapy and screened again at least once every 3 months and upon diagnosis of any other sexually transmitted infections; adherence should also be closely monitored (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents weighing ≥35 kg: Oral: Emtricitabine 200 mg and tenofovir alafenamide 25 mg per tablet: One tablet once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51108459"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents weighing ≥14 kg:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Use is not recommended.</p></div>
<div class="block dohp drugH1Div" id="F51108460"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents weighing ≥14 kg:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage recommendations in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F46539117"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for HIV-1 preexposure prophylaxis in adults. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2%), diarrhea (5%), nausea (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (2%), headache (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Decreased bone mineral density (≥5% decrease at lumbar spine: 4%; ≥7% decrease at femoral neck: 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum triglycerides</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Exacerbation of hepatitis B</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Fanconi’s syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proximal tubular nephropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, renal tubular necrosis</p></div>
<div class="block coi drugH1Div" id="F46363038"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">As preexposure prophylaxis in patients with unknown or HIV-1 positive status.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to emtricitabine, tenofovir alafenamide, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F46507949"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barré syndrome, autoimmune hepatitis) later in therapy; further evaluation and treatment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lactic acidosis/hepatomegaly: Lactic acidosis and severe hepatomegaly with steatosis, sometimes fatal, have been reported with use of nucleoside analogues, alone or in combination with other antiretrovirals. Suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (marked transaminase elevation may/may not accompany hepatomegaly and steatosis).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: Renal toxicity (acute renal failure, Fanconi syndrome, and/or proximal renal tubulopathy) has been reported with use of tenofovir prodrugs; patients with impaired renal function and those with concurrent or recent nephrotoxic therapy (including nonsteroidal anti-inflammatory drug use) are at an increased risk. Discontinue use in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic hepatitis B: <b>[US Boxed Warning]: Acute, severe exacerbations of hepatitis B virus (HBV) have been reported in HBV-infected patients following discontinuation of antiretroviral therapy. Closely monitor hepatic function with clinical and laboratory follow-up for at least several months in patients infected with HBV who discontinue this therapy. If appropriate, anti-HBV therapy may be warranted,</b> especially in patients with advanced hepatic disease or cirrhosis (post-treatment HBV exacerbations may lead to hepatic decompensation and liver failure). All patients with HIV should be tested for HBV prior to or when initiating treatment; HBV-uninfected patients should be offered vaccination.</p>
<p style="text-indent:-2em;margin-left:4em;">• Comprehensive prevention program: Preexposure prophylaxis (PrEP) should be accompanied by a comprehensive HIV-1 prevention program (eg, risk reduction counseling, consistent and correct condom use, regular sexually transmitted infection testing), with particular emphasis on medication adherence.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use is not recommended in patients with CrCl &lt;30 mL/minute (unless receiving hemodialysis). Safety and efficacy of concurrent administration with an HIV-1 protease inhibitor plus ritonavir or cobicistat has not been established in patients with CrCl &lt;15 mL/minute (with or without hemodialysis).</p>
<p style="text-indent:-2em;margin-left:4em;">• Resistance risk with preexposure prophylaxis: <b>[US Boxed Warning]: Confirm HIV-1 negative status immediately before and at least every 3 months during therapy</b>, and upon diagnosis of any other sexually transmitted infection. <b>Do not start PrEP if signs or symptoms of acute HIV-1 infection are present unless HIV-1 negative status is confirmed</b> by a test approved by the Food and Drug Administration (FDA) as an aid to detect HIV-1 infection (including acute or primary infection). <b>Risk of drug resistant HIV-1 variants with PrEP use if patient had undetected acute HIV-1 infection:</b> Some HIV-1 tests do not detect acute HIV-1 infection. Screen PrEP candidates for signs/symptoms of acute HIV-1 infection and potential exposure events within 1 month of starting PrEP. If signs/symptoms or potential exposure events exist, use a test approved by the FDA for diagnosing acute or primary HIV-1 infection before initiating PrEP. During use of PrEP, if a screening test indicates possible HIV-1 infection or if symptoms of acute HIV-1 infection develop after a potential exposure, convert the HIV-1 PrEP regimen to an HIV-1 treatment regimen until negative infection status is confirmed.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878815"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Emtricitabine-associated hyperpigmentation may occur at a higher frequency in pediatric patients compared to adults (children: 32%; adults: 2% to 6%).</p>
<p style="text-indent:0em;margin-top:2em;">Through disruption in vitamin D metabolism, decreases in bone mineral density (BMD) have been observed with tenofovir alafenamide (TAF) after 48 weeks of treatment; however, the incidence and negative impact on BMD is less than that observed with tenofovir disoproxil fumarate (TDF). Additionally, TAF is associated with less renal toxicity than TDF but equal antiviral efficacy. A higher incidence of dyslipidemia has been reported with TAF than TDF. TAF is preferred over TDF whenever possible; do not use TAF and TDF concomitantly (HHS [pediatric] 2019).</p></div>
<div class="block foc drugH1Div" id="F46443600"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Descovy: Emtricitabine 120 mg and tenofovir alafenamide 15 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Descovy: Emtricitabine 200 mg and tenofovir alafenamide 25 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p></div>
<div class="block geq drugH1Div" id="F46443598"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F46817116"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Descovy Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120-15 mg (per each): $88.09</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200-25 mg (per each): $88.09</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872169"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Descovy: Emtricitabine 200 mg and tenofovir alafenamide 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Descovy: Emtricitabine 200 mg and tenofovir alafenamide 25 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p></div>
<div class="block adm drugH1Div" id="F46507963"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or without food.</p></div>
<div class="block admp drugH1Div" id="F52614645"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with or without food.</p></div>
<div class="block meg drugH1Div" id="F53739399"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Descovy: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F208215s019lbl.pdf%23page%3D37&amp;token=L%2FWGT1g5TL5e0GUbNZcob%2BfD%2B9B1oBEyX47XfFIbEjo5TEZvm4SFWCHxK%2BaRi0sJUUikBXLJQlO%2FtEePVaTkHo7VFRaagZI2FhasreyKM%2Bvt3bYatRHIx92m7KldpLDG&amp;TOPIC_ID=107645" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208215s019lbl.pdf#page=37</a></p></div>
<div class="block use drugH1Div" id="F46363037"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment:</b> Treatment of HIV-1 infection in combination with other antiretroviral agents in adults and pediatric patients weighing ≥35 kg; in combination with other antiretroviral agents (other than protease inhibitors that require a CYP3A inhibitor) in pediatric patients weighing ≥14 kg and &lt;35 kg.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, preexposure prophylaxis:</b> Preexposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in at-risk adults and adolescents weighing ≥35 kg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Limitations of use:</i> Not indicated for individuals at risk from receptive vaginal sex.</p></div>
<div class="block off-label drugH1Div" id="F54119770"><span class="drugH1">Use: Off-Label: Adult</span><p>HIV-1/hepatitis B co-infection, treatment</p></div>
<div class="block cyt drugH1Div" id="F46440187"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F46440184"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acyclovir-Valacyclovir: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Acyclovir-Valacyclovir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adefovir: May diminish the therapeutic effect of Tenofovir Products. Adefovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Adefovir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Betibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cidofovir: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Cidofovir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May increase the serum concentration of Tenofovir Alafenamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Elivaldogene Autotemcel.  Management: Avoid use of antiretroviral medications for at least one month, or for the amount of time required for elimination of the retroviral medication, prior to stem cell mobilization and until the all apheresis cycles are finished<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganciclovir-Valganciclovir: Tenofovir Products may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Tenofovir Alafenamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of Tenofovir Products. Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose due to a potential risk of acute renal failure. Diclofenac appears to confer the most risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the nephrotoxic effect of Tenofovir Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OXcarbazepine: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of Tenofovir Alafenamide. Management: Consider alternatives to the use of P-gp inducers with tenofovir alafenamide. If combined, monitor for reduced tenofovir alafenamide concentrations and efficacy, and for the development of resistance.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May increase the serum concentration of Tenofovir Alafenamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Tenofovir Products may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F52942435"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">The Health and Human Services (HHS) perinatal HIV guidelines consider emtricitabine and tenofovir alafenamide preferred agents for use in patients with HIV who are not yet pregnant but are trying to conceive (HHS [perinatal] 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block pri drugH1Div" id="F46507946"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">The Health and Human Services (HHS) perinatal HIV guidelines consider this combination to be a preferred nucleoside reverse transcriptase inhibitor backbone for initial therapy in antiretroviral-naive pregnant patients. In addition, this combination is preferred for use in pregnant patients with HIV who have had antiretroviral therapy (ART) in the past but are restarting, or who require a new ART regimen (due to poor tolerance or poor virologic response of current regimen). Patients who become pregnant while taking this combination may continue if viral suppression is effective and the regimen is well tolerated.</p>
<p style="text-indent:0em;margin-top:2em;">Emtricitabine and tenofovir alafenamide are recommended as part of a preferred regimen when early (acute/recent) HIV infection is detected during pregnancy; genotyping may be required if the person had prior use of long acting cabotegravir for pre-exposure prophylaxis (PrEP).</p>
<p style="text-indent:0em;margin-top:2em;">The HHS perinatal guidelines also recommend emtricitabine plus tenofovir alafenamide as a component of regimens for HIV/hepatitis B virus–coinfected patients who are pregnant (HHS [perinatal] 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block brc drugH1Div" id="F46507948"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Emtricitabine and tenofovir alafenamide are present in breast milk (HHS [perinatal] 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block mop drugH1Div" id="F46507965"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CD4 count, HIV RNA plasma levels; serum creatinine, estimated CrCl, urine glucose, urine protein (prior to or when initiating therapy and as clinically indicated during therapy); serum phosphorus (in patients with chronic kidney disease); hepatic function tests; testing for hepatitis B virus (HBV) is recommended prior to or when initiating antiretroviral therapy. Patients with HIV and HBV coinfection should be monitored for several months following therapy discontinuation.</p>
<p style="text-indent:0em;margin-top:2em;">HIV-1 preexposure prophylaxis (CDC 2021): Documented negative HIV test (≤1 week before initiating or reinitiating PrEP, at least every 3 months while taking PrEP, and following discontinuation of PrEP); assess symptoms of side effects and acute HIV infection (every 3 months); testing for HBV (prior to initiation); lipid panel (prior to initiation, then every 12 months).</p></div>
<div class="block pha drugH1Div" id="F46507952"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Nucleoside and nucleotide reverse transcriptase inhibitor combination; emtricitabine is a cytidine analogue while tenofovir alafenamide fumarate (TAF) is an analog of adenosine 5'-monophosphate. Each drug interferes with HIV viral RNA dependent DNA polymerase activities resulting in inhibition of viral replication.</p></div>
<div class="block phk drugH1Div" id="F46507954"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Emtricitabine: &lt;4%; TAF: ~80%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Emtricitabine: Not significantly metabolized; TAF: Primarily intracellular metabolism; minimal extent by CYP3A</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Emtricitabine: 10 hours; TAF: 0.51 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Emtricitabine: 3 hours; TAF: 1 hour</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Emtricitabine:  Urine (70%); feces (13.7%); TAF: Urine (&lt;1%), feces 31.7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Emtricitabine and tenofovir may be eliminated by both glomerular filtration and active tubular secretion</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet.</i> 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-alafenamide-and-emtricitabine-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21270743">
<a name="21270743"></a>Centers for Disease Control and Prevention (CDC). Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. <i>MMWR Morb Mortal Wkly Rep.</i> 2011;60(3):65-68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-alafenamide-and-emtricitabine-drug-information/abstract-text/21270743/pubmed" id="21270743" target="_blank">21270743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23760186">
<a name="23760186"></a>Centers for Disease Control and Prevention (CDC). Interim guidance: preexposure prophylaxis for the prevention of HIV infection: PrEP for injecting drug users. <i>MMWR Morb Mortal Wkly Rep.</i> 2013;62(23):463-465.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-alafenamide-and-emtricitabine-drug-information/abstract-text/23760186/pubmed" id="23760186" target="_blank">23760186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC): US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 Update: a clinical practice guideline. <a href="https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf" target="_blank">https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf</a>. Published December 2021. Accessed July 18, 2022.</div>
</li>
<li>
<div class="reference">
                  Descovy (emtricitabine and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Descovy.1">
<a name="Descovy.1"></a>Descovy (emtricitabine and tenofovir alafenamide) [product monograph]. Mississauga, Ontario, Canada: Gilead Sciences Canada Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30555051">
<a name="30555051"></a>Eron JJ Jr, Lelievre JD, Kalayjian R, et al. Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. <i>Lancet HIV</i>. 2018:S2352-3018(18)30296-0. doi:10.1016/S2352-3018(18)30296-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-alafenamide-and-emtricitabine-drug-information/abstract-text/30555051/pubmed" id="30555051" target="_blank">30555051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32711800">
<a name="32711800"></a>Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. <i>Lancet</i>. 2020;396(10246):239-254. doi:10.1016/S0140-6736(20)31065-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-alafenamide-and-emtricitabine-drug-information/abstract-text/32711800/pubmed" id="32711800" target="_blank">32711800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28885375">
<a name="28885375"></a>Novick TK, Choi MJ, Rosenberg AZ, McMahon BA, Fine D, Atta MG. Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: a case report. <i>Medicine (Baltimore).</i> 2017;96(36):e8046. doi:10.1097/MD.0000000000008046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-alafenamide-and-emtricitabine-drug-information/abstract-text/28885375/pubmed" id="28885375" target="_blank">28885375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27673443">
<a name="27673443"></a>Post FA, Tebas P, Clarke A, et al. Brief report: switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study. <i>J Acquir Immune Defic Syndr.</i> 2017;74(2):180-184. doi:10.1097/QAI.0000000000001186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-alafenamide-and-emtricitabine-drug-information/abstract-text/27673443/pubmed" id="27673443" target="_blank">27673443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26627107">
<a name="26627107"></a>Pozniak A, Arribas JR, Gathe J, et al; GS-US-292-0112 Study Team. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study. <i>J Acquir Immune Defic Syndr.</i> 2016;71(5):530-537. doi:10.1097/QAI.0000000000000908<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-alafenamide-and-emtricitabine-drug-information/abstract-text/26627107/pubmed" id="26627107" target="_blank">26627107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33052386">
<a name="33052386"></a>Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA Panel. <i>JAMA</i>. 2020;324(16):1651-1669. doi:10.1001/jama.2020.17025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-alafenamide-and-emtricitabine-drug-information/abstract-text/33052386/pubmed" id="33052386" target="_blank">33052386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28867499">
<a name="28867499"></a>Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. <i>Lancet</i>. 2017;390(10107):2073-2082. doi:10.1016/S0140-6736(17)32340-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-alafenamide-and-emtricitabine-drug-information/abstract-text/28867499/pubmed" id="28867499" target="_blank">28867499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet.</i> 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-alafenamide-and-emtricitabine-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34419091">
<a name="34419091"></a>Ueaphongsukkit T, Gatechompol S, Avihingsanon A, et al. Tenofovir alafenamide nephrotoxicity: a case report and literature review. <i>AIDS Res Ther</i>. 2021;18(1):53. doi:10.1186/s12981-021-00380-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-alafenamide-and-emtricitabine-drug-information/abstract-text/34419091/pubmed" id="34419091" target="_blank">34419091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. <a href="http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf" target="_blank">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</a>. Updated December 18, 2019. Accessed December 18, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. <a href="https://aidsinfo.nih.gov/guidelines/html/2/pediatric-treatment-guidelines/0" target="_blank">https://aidsinfo.nih.gov/guidelines/html/2/pediatric-treatment-guidelines/0</a>. Updated September 12, 2019. Accessed November 2, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Perinatal_GL.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Perinatal_GL.pdf</a>. Updated January 31, 2023. Accessed February 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24492366">
<a name="24492366"></a>Valade E, Tréluyer JM, Bouazza N, et al. Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients. <i>Antimicrob Agents</i>
<i>Chemother.</i> 2014;58(4):2256-2261. doi:10.1128/AAC.02058-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenofovir-alafenamide-and-emtricitabine-drug-information/abstract-text/24492366/pubmed" id="24492366" target="_blank">24492366</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 107645 Version 150.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
